Myriad's Downside Case Might Not Matter By: Benzinga via Benzinga April 01, 2015 at 15:25 PM EDT In a report published Wednesday, Barclays analysts maintained an Overweight rating on Myriad Genetics Inc (NASDAQ: MYGN), with a price ... Read More >> Related Stocks: Myriad Genetics Inc